• Français
  • Search
  • Conference
    • CAHR 2023
    • Future CAHR Conferences
    • Mark Wainberg Lecture
    • Past Conferences
  • Awards
    • HCP Travel Awards Competition
    • Mark Wainberg Fund
    • CAHR-CANFAR Excellence in Research Awards
    • Red Ribbon Award
    • Funding Archive
    • Funding Landscape
  • Training
    • Workshops
    • Webinars
      • HIV and COVID-19: Clinical Considerations for Health Care Professionals in Canada
      • HIV and COVID-19: Clinical Considerations for Health Care Professionals in Canada PART 2
    • Clinical Summaries
    • E-Learning Modules
    • Posters and Presentations
    • Community Based Research
    • Student Profiles
    • Training Workshops: Consultation Report
    • Publications / Resources
  • About CAHR
    • Who We Are
    • President’s Message
    • Board of Directors
    • Become a Member
    • CAHR Annual General Meeting
    • CAHR Strategic Plan 2020 – 2025
    • Staff
    • Contact
  • Media
    • CAHR News
    • Media
    • Featured Researchers
  • Conference
    • CAHR 2023
    • Future CAHR Conferences
    • Sponsors & Exhibitors
    • Mark Wainberg Lecture
    • Past Conferences
  • Awards
    • HCP Travel Awards Competition
    • Mark Wainberg Fund
    • CAHR-CANFAR Excellence in Research Awards
    • Red Ribbon Award
    • Funding Archive
    • Funding Landscape
  • Training
    • Workshops
    • Webinars
      • HIV and COVID-19: Clinical Considerations for Health Care Professionals in Canada
      • HIV and COVID-19: Clinical Considerations for Health Care Professionals in Canada PART 2
    • Clinical Summaries
    • E-Learning Modules
    • Posters and Presentations
    • Community Based Research
    • Student Profiles
    • Training Workshops: Consultation Report
    • Publications / Resources
  • About CAHR
    • Who We Are
    • President’s Message
    • Board of Directors
    • CAHR Board Trainee
    • Become a Member
    • CAHR Strategic Plan 2020 – 2025
    • CAHR Annual General Meeting
    • Call for Nominations: CAHR Board of Directors
    • Staff
    • Contact
  • Media
    • CAHR News
    • Media

Dr. Éric Cohen

The Nuts and Bolts of Virus-Host Interactions
Institut de recherches cliniques de Montréal and Université de Montréal

Dr. Éric Cohen, Canada Research Chair in Human Retrovirology and Professor at the Institut de recherches cliniques de Montréal and at Université de Montréal, digs right down to the basic levels of viral-host relationships. It’s the complexity of these relationships and what they tell us about the virus and the human immune system that has kept him in this field of research for almost 30 years. Now, as the leader of a team supported by the Canadian Initiative for HIV Cure Research, the Canadian HIV Cure Enterprise (CanCURE), Dr. Cohen is applying his knowledge in basic science to strategies for preventing HIV from establishing and maintaining infection. “Any cure for HIV will be based on interfering with the ability of the virus to persist in the host,” explains Dr. Cohen. “If we identify critical virus-host interactions that we can target, we could eventually develop anti-persistence strategies.”

Replication and transmission efficiency of HIV is affected by two things; the ability of the virus to have access to host factors (cellular proteins that HIV depends on for replication and transmission) and the virus’ ability to counter host defense mechanisms. On a molecular level, human cells encode antiviral proteins (called restriction factors) that suppress HIV replication in human cells. At the same time HIV has evolved a set of proteins (accessory proteins) whose role is to modify the cellular environment to promote immune evasion—paving the way for efficient viral replication and transmission. Dr. Cohen and his lab study the interplay between viral accessory proteins (specifically VIF, VPR, VPU and Nef) and host antiviral proteins.

His recent work has investigated the role of the viral protein U (VPU) which appears to counteract the antiviral activity of a restriction factor called Tetherin. Tetherin’s function is to prevent virus particles from budding off the cell surface and moving on to infect other cells, while VPU promotes the release of these virus particles. But VPU also plays a role in inhibiting the host immune response. “Besides understanding how these restriction factors inhibit HIV replication, we are also looking at how these factors promote other types of responses,” explains Dr. Cohen. “By downregulating Tetherin at the cell surface, it negatively affects antibody-dependent cell-mediated cytotoxicity (ADCC, an innate immune response) which means that VPU is protecting infected cells from an immune response.”

Dr. Cohen’s work is also investigating the relationship between VPU and plasmacytoid dendritic cells (PDCs)—human cells that are involved in the antiviral immune response. “PDCs can sense the virus and basically trigger antiviral defenses in the form of production of interferon, preventing the virus from disseminating.” But natural stop-gaps exist to prevent the production of too much interferon and Dr. Cohen suspects that VPU is exploiting this pathway to prevent an effective immune response. The results of this work are forthcoming.

Though his research investigates the most basic level of HIV-host interaction, Dr. Cohen moves upwards in complexity as he goes, to ensure his work has real world applications. “Once we make basic discoveries in experimental models, we go into primary cells and eventually move into a humanized mouse model (a mouse with a human immune system) where we look at things in vivo. Eventually, we use biological samples from HIV infected individuals. We work on very basic mechanisms and then validate them in the most physiologically relevant system that we can have.” HIV’s ability to establish viral reservoirs in long-lived immune cells despite antiretroviral therapy represents the primary source of viral persistence and the barrier to an HIV cure. Dr. Cohen’s hope is that by elucidating the fundamental molecular pathways of virus-host interactions, we can prevent the establishment of infection and reservoirs right from the start.

The Canadian Association for HIV Research (CAHR), the CIHR HIV/AIDS Research Initiative, the Canadian Foundation for AIDS Research (CANFAR), the CIHR Canadian HIV Trials Network (CTN) and the Canadian HIV Vaccine Initiative (CHVI) Research and Development Alliance Coordinating Office (ACO) would like to thank Dr. Cohen for his significant contributions to our understanding of HIV. His work is part of a larger Canadian research effort that is making a difference in the lives of those affected by HIV in Canada and around the world.

Our Mission

  • Promote excellence in HIV research
  • Foster collaboration and cooperation among HIV research communities, including basic science, clinical science, epidemiology & public health and social science
  • Promote education and the development of new researchers
  • Provide a unified voice for Canadian HIV researchers and engage diverse stakeholders (community, industry, Government, NGO’s etc.) in ongoing dialogue and knowledge exchange to ensure that HIV research remains responsive to their needs
CAHR 2023 Conference Logo

CAHR 2023
April 27 to 30, 2023

Learn More

Recent News

  • When you’re registering for the e @AMMICana - CACMID annual conference on infectious diseases and diagnostic microbiology (March 28-31, 2023 in Toronto), remember that CAHR members receive a $35 discount on the full non-member conference registration! ammi.ca/en/annual-conf…
  • Last day to apply for the CAHR-@CANFAR Excellence in Research Awards! cahr-acrv.ca/awards/excelle… Dernier jour pour postuler aux Bourses d'excellence en recherche CAHR-@CANFAR! cahr-acrv.ca/fr/prix/prix-d… https://t.co/szhBdhZuRZ
  • Remember to apply for the CAHR-RV-@CAN Excellence in Research Awards by January 26th! cahr-acrv.ca/awards/excelle… Après le 26 janvier nous n’acceptons plus de candidatures aux Prix d'excellence en recherche ACRV-RV-@CAN! cahr-acrv.ca/fr/prix/prix-d… https://t.co/bhgkCEDBmD
  • Reminder: Apply Now – A workshop on “Jumpstarting your Participatory Social-Behavioural Health Intervention” cahr-acrv.ca/wp-content/upl… UmnUV @CBRC weets @CAT EInfo @Giving_
  • Rappel : Postulez maintenant - Un atelier sur « Lancez votre intervention participative en santé sociocomportementale ». cahr-acrv.ca/wp-content/upl… ZS @CBRCtwe ts @CATIEI fo @Giving_It_
  • Se souvenir de Chris Bunting
Subscribe to the CAHR Newsletter

About CAHR

With a membership of more than 1,000 researchers and others interested in HIV research, the Canadian Association for HIV Research (CAHR) is the leading organization of HIV/AIDS researchers in Canada. CAHR is the organizing body for the Annual Canadian Conference on HIV/AIDS Research (CAHR Conference).

CAHR encourages Canadian researchers to be leaders in knowledge translation and to effectively respond both to the Canadian and global HIV/AIDS epidemics. Since its founding in 1991, CAHR has promoted excellence in HIV research, including mentorship and career development of investigators entering the field.

CAHR fosters collaboration and co-operation among HIV research communities, including basic, clinical and social sciences, epidemiology and public health. CAHR also engages people living with HIV/AIDS and AIDS service organizations in ongoing dialogue and information exchange to ensure that HIV/AIDS research remains responsive to the epidemic and its stakeholders.

CAHR is a registered charity.

Links

  • Who We Are
  • Conference
  • Awards
  • Workshops
  • Featured Researchers
  • Student Profiles
  • CAHR News

Contact

For more information or to make a comment, please contact us:

Canadian Association for HIV Research

440 Laurier Avenue West, Suite 200
Ottawa, Ontario K1R 7X6

1-888-374-CAHR (2247)
info@cahr-acrv.ca
  • Media
  • Contact
  • Français